当前位置:首页 >英文主页 >中英对照 > 报告详情

毕马威:2026创造价值:全球能力中心如何化能力为终端患者影响研究报告(英文版)(32页).pdf

上传人: 1****1 编号:1126744 2026-02-25 32页 2.89MB

下载:

1、 2026KPMG.Make the Difference.Making it matter:How GCCs Transform Capability into End-Patient ImpactHealthcare and Life Sciences GCCs:A Discussion PaperIn collaboration withMaking it matter:How GCCs Transform Capability into End-Patient Impact2 2026 KPMG Assurance and Consulting Services LLP,an Indi

2、an Limited Liability Partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited,a private English company limited by guarantee.All rights reserved.3Making it matter:How GCCs Transform Capability into End-Patient Impact 2026 KP

3、MG Assurance and Consulting Services LLP,an Indian Limited Liability Partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited,a private English company limited by guarantee.All rights reserved.ContentsPageForeword04Landscape

4、,evolution and ecosystem05-10Pharma and Life Sciences GCCs:Value chain,technology disruption,Centres of Excellence its strategic impact 12-15Health tech and Medical devices GCCs:Value chain,technology disruption,Centres of Excellence its strategic impact 17-20Industry case studies21-28Future outlook

5、29-30Acknowledgements31 2026 KPMG Assurance and Consulting Services LLP,an Indian Limited Liability Partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited,a private English company limited by guarantee.All rights reserved.

6、4Making it matter:How GCCs Transform Capability into End-Patient Impact 2026 KPMG Assurance and Consulting Services LLP,an Indian Limited Liability Partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited,a private English c

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **全球医疗健康GCC生态**:印度拥有150+医疗健康与生命科学GCC,超250个单元,雇员30万,占全球最大份额(250+单元),中国(100+)、波兰(50+)等次之。 2. **战略转型**:从成本中心转向创新引擎,印度GCC主导药物研发(AI加速靶点发现)、临床试验(患者招募效率提升28%)、监管合规(审批周期缩短79%)等全链条。 3. **技术赋能**:AI/ML渗透率达60%,推动R&D成本降20-30%,临床试验周期缩短1-2年,如诺和诺德印度中心将口服Wegovy®申报准备时间从6个月压缩至12天。 4. **区域集群**:班加罗尔(25-30%)、海得拉巴(20-25%)为核心,新兴枢纽如浦那、艾哈迈达巴德崛起,40%企业采用多城模式优化风险与专长。 5. **患者影响**:加速药物上市(如糖尿病疗法研发提速30-40%),降低成本(医疗设备价格降1/3),提升可及性(如便携ECG设备售超7500台)。
**GCC如何创新?** **患者受益在哪?** **成本如何降低?**
客服
商务合作
小程序
服务号
折叠